Vistagen Therapeutics, Inc. (VTGN)

NASDAQ: VTGN · Real-Time Price · USD

2.170

+0.120 (5.85%)

Apr 23, 2025, 4:00 PM EDT - Market closed

5.85% (1D)

Market Cap	62.63M
Revenue (ttm)	698,000
Net Income (ttm)	-47.30M
Shares Out	28.86M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	112,480
Open	2.130
Previous Close	2.050
Day's Range	2.120 - 2.180
52-Week Range	1.900 - 5.000
Beta	0.56
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 10, 2025

About VTGN

Vistagen Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for psychiatric and neurological disorders. The company’s product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. It also develops PH80, a hormone-free, odorless, and tasteless synthetic investigational neuroactive pherine nasal spra... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Employees 40

Stock Exchange NASDAQ

Ticker Symbol VTGN

Website https://www.vistagen.com

Full Company Profile

Financial Performance

Financial Statements

News

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...

6 days ago - Business Wire

Vistagen Therapeutics, Inc. (VTGN)

About VTGN

Financial Performance

News

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Vistagen to Present at the Stifel 2024 Healthcare Conference

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript